Tenderwize
Back to tender search

Non-exclusive rebate agreement for glatiramer acetate prefilled syringes

AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen·Dresden, Germany·Deadline Jun 30, 2027 · 265 days left·Open·Supplies·Framework
Sign up to saveOpen documents
Original notice title

Germany – Pharmaceutical products – Abschluss nicht exkl. AM-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Glatirameracetat in der Darreichungsform Fertigspritze (ATC-Code nach WHO: L03AX13)

52/100

Opportunity Score

Needs reviewMedium complexity
SuppliesFrameworkOpen
Why this score?

Opportunity

52 / 100

Complexity

58 / 100

Risk factors

Structured data marks electronic submission as not allowed, while the notice text says communication and transmission o...

The notice references project-space documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfri...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Jun 30, 2027

Overview

Moderate opportunity

Key Facts

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Non-exclusive rebate agreements under § 130a(8) SGB V for glatiramer acetate in prefilled syringes.
  • Open-house model with participation open to all eligible pharmaceutical companies during the participation period.
Show full summary

Open-house procurement for non-exclusive pharmaceutical rebate agreements on glatiramer acetate prefilled syringes (ATC L03AX13) in Germany. The contract is a supplies framework-type arrangement with unlimited participation during the participation period, no individual negotiations, no exclusivity, and unknown call-off volume. Participation is electronic via DTVP project space, but submission is marked as not allowed in the structured data, which appears inconsistent with the document text and should be clarified. No detailed procurement document text beyond the TED XML notice was provided, so document-based requirements may be incomplete.

Risks

Structured data marks electronic submission as not allowed, while the notice text says communication and transmission o...

The notice references project-space documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfri...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Applicant must be a pharmaceutical entrepreneur for the offered medicines under German medicines law, as stated in the notice.

Eligibility

  • Submission of the completed self-declaration on the absence of exclusion grounds under §§ 123, 124 GWB.

Administrative

  • Submission of the Russia sanctions self-declaration for the bidder and any involved company.

Buyer

Location

Dresden, DEU

Buyer profile

Open profile

Identifier

DE256878834

Activity

Health

Lots (1)

LOT-0001

Non-exclusive rebate agreement for glatiramer acetate prefilled syringes

Open-house lot for non-exclusive rebate agreements for the pharmaceutical product glatiramer acetate in prefilled syringe form. Scope is supplies of medicinal products in Germany, with participation open to all interested pharmaceutical companies that meet and accept the stated conditions. No exclusivity or guaranteed minimum purchase volume is provided.

SuppliesFrameworkEU fundedElectronic submission

Location

Dresden, Germany

Duration

Jun 2025 - Jun 2027

Category

Pharmaceutical products

Deadline

Deadline Jun 30, 2027

Procurement Details

Publication date
17 Apr 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
256358-2025

Documents (1)

Procurement document 1

Similar tenders

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.

Dec 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30